For the quarter ending 2025-11-30, BZYR had $1,234 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-11-30 | 2025-08-31 | 2025-05-31 |
|---|---|---|---|
| Net loss | -328,862 | -333,867 | -331,451 |
| Prepaids | -300 | -300 | 700 |
| Accounts payable | 21,158 | -1,739 | 8,665 |
| Accrued liabilities | -22,452 | 1,404 | 20,088 |
| Net cash used by operating activities | -823,106 | -94,907 | -49,143 |
| Contribution of capital | 86,307 | 95,017 | 49,117 |
| Fda clinical trial expenses paid directly by s.r. burzynski m.d., ph.d | 244,783 | 238,995 | 254,255 |
| Net cash provided by financing activities | 824,340 | 95,017 | 49,117 |
| Net increase (decrease) in cash | 1,234 | 110 | -26 |
| Cash and cash equivalents at beginning of period | 931 | 847 | - |
| Cash and cash equivalents at end of period | 2,165 | 931 | - |
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)